Drug Profile
ALX 101
Alternative Names: A-110; ALX-101; LXR agonistLatest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Alexar Therapeutics
- Developer Ralexar Therapeutics
- Class Skin disorder therapies
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 14 Oct 2021 ALX 01 is still in phase II trials for Atopic dermatitis (In children, In adolescents, In adults, In the elderly) in USA (NCT03859986)
- 01 Mar 2019 Ralexar Therapeutics initiates enrolment in a phase II trial for Atopic dermatitis in USA (Topical) (NCT03859986)
- 29 Jun 2018 Ralexar Therapeutics completes a phase II trial in Atopic dermatitis in USA (Topical) (NCT03175354)